Abstract: Asian countries bear the greatest burden of the disease, with a majority (59%) of rabies-related deaths occurring in Asia. In order to promote best practices, we summarized national human vaccination guidelines across this region, to highlight differences and similarities and to discuss the aspects that would benefit from updates. National management guidelines for rabies were retrieved from various sources to extract information on rabies pre-and post-exposure prophylaxis (PrEP, and PEP), booster vaccination, and route of administration. Rabies guidelines recommendations for wound management and PrEP across Asia are broadly aligned to the World Health Organization (WHO) guidelines. For PEP, the 5-dose Essen, and the 4-dose Zagreb are the regimens of choice for intramuscular (IM), and the Thai Red Cross regimen for intradermal (ID), administration. Several national guidelines have yet to endorse ID vaccine administration. Most guidelines recommend rabies immunoglobulin in category III exposures. Booster recommendations are not included in all guidelines, with limited clarity on booster requirement across the spectrum of risk of rabies exposure. In conclusion, national recommendations across Asian countries differ and while some guidelines are closely aligned to the WHO recommendations, resource-saving ID administration and use of rational abbreviated schedules have yet to be endorsed.
•
The recommended practices for rabies pre-and post-exposure prophylaxis vary widely from country to country in Asia.
• Overall, the WHO recommendations for wound management are consistent in national guidelines. The post-exposure prophylaxis (PEP) 5-dose Essen and 4-dose Zagreb intramuscular (IM) regimens are uniformly recommended.
The value of intradermal (ID) administration in reducing costs is not considered in several country guidelines.
In the majority of the national recommendations, concurrent administration of rabies immunoglobulin (RIG) in category III exposures is recommended; however, there are concerns regarding availability and cost.
Booster recommendations are not included in all guidelines, with limited clarity on booster requirement across the spectrum of risk of rabies exposure.
Limited recommendations are available for special populations including pregnant women, aged population, and immunocompromised patients.
Introduction
Despite being entirely preventable, human rabies is estimated to cause 59,000 global deaths annually, of which 59% occur in the Asia region [1, 2] . Bites from infected dogs cause 95% of human rabies deaths, 40% of which occur in children [3, 4] . If prompt vaccination is not given, rabies infection causes death in virtually all cases [3] . However, the death toll can be considerably reduced through access to post-exposure prophylaxis (PEP), consisting of wound cleaning, rabies immunoglobulin (RIG) and vaccination. Additionally, the broader use of pre-exposure (PrEP) vaccination and mass dog vaccination would further reduce deaths and help control and eventually eliminate dog-mediated human rabies [1, 4, 5] . Human and canine rabies control are therefore interdependent, and experience has shown that a collaboration between human and animal health sectors is required to enhance cost-effectiveness of rabies control measures, and effectively reduce rabies incidence and associated societal burden [6] [7] [8] . This approach, under the "One Health" framework, with the goal to eliminate dog-mediated rabies by 2030, is endorsed and jointly advocated by the World Health Organization (WHO), the World Organisation for Animal Health (OIE), the Food and Agriculture Organization of the United Nations (FAO), and the Global Alliance for Rabies Control (GARC) [5] .
Activities aiming to control rabies disease have been initiated, and some governments of disease-endemic countries have committed to its elimination by 2030. In this process, it is important to have reliable country-level epidemiology data, active surveillance systems seeking to register any new cases, appropriate vaccine requirement forecasting, and other such tools that can track progress made towards achieving this goal [3] .
However, national reporting systems and public awareness are often lacking [2, 3] . People living in countries with endemic rabies disease are sometimes insufficiently aware of the risk and the need for vaccination. Furthermore, the total cost of vaccination-including, for instance, travel expenses to-and-from the vaccination center, and lost work income-is a major consideration for these individuals [2, 4, [9] [10] [11] [12] [13] . Moreover, healthcare personnel are sometimes unaware of appropriate wound management, of PEP regimens, and of the existence of PrEP [4, 14] .
In this context, safe and effective, yet cost-saving and/or shorter regimens are appealing. Both intramuscular (IM) and intradermal (ID) vaccine schedules are endorsed by the WHO (Table 1) . ID administration requires fewer vaccine vials than IM, reducing the direct vaccination cost by 60-80% [13] . For optimal cost benefit of the ID administration, the health seeking rate should be sufficiently high to utilize the entire vial within 6-8 h [1, 13] . Importantly, patients receiving IM or ID cell culture rabies vaccination should reach 0.5 IU/mL or higher titers of rabies virus neutralizing antibodies (RVNA) within 14 days from vaccination (the level considered indicative of adequate immune response to vaccination). Both vaccines administration methods demonstrate acceptable safety profiles. In this respect, in an otherwise healthy population, ID vaccination is clinically equivalent to that of IM [13] . The shorter, dose-sparing vaccination regimens are equally effective alternatives, improving compliance and allowing for more animal bite victims to successfully complete a full vaccination course [1, 13, [15] [16] [17] [18] [19] [20] . However, these have not yet been endorsed by all countries with endemic disease in Asia region. To achieve the 2030 goal for rabies elimination, national PrEP and PEP strategies and clear public health guidelines following WHO recommendations must be implemented to increase access to vaccination with optimal efficacy of the vaccine and control the disease [1, 4] . A Working Group on rabies vaccines and rabies immunoglobulins established by the WHO Strategic Advisory Group of Experts on Immunization (SAGE) is currently reviewing new evidence on country practices in the use of RIG, PrEP, and the cost-effectiveness of the interventions. The findings will be discussed and SAGE will consider recommendations on the WHO position on rabies during its October 2017 meeting [21, 22] . 
ID vaccination regimen §
The updated Thai Red Cross regimen (2-2-2-0-2): Injections of 0.1 mL at two sites (deltoid and thigh) on each of days 0, 3, 7, and 28
Short Post-Exposure Prophylaxis for Previously Vaccinated Individuals
Exposed or re-exposed individuals, or individuals with rabies-virus neutralizing antibody titers of ≥0. [13] and WHO Expert Consultation on Rabies (2013) [1] ; Abbreviations: CCEEV, cell culture vaccine and embryonated egg-based vaccines; CCV, cell culture vaccine; HDCV, human diploid cells vaccine; ID, intradermal; IM, intramuscular; PCECV, purified chick embryo cell vaccine; PDEV, purified duck embryo vaccine; PVRV, purified Vero rabies vaccine; RIG, rabies immunoglobulin; WHO, World Health Organization; * within 6-8 h, several individuals should be vaccinated in order to utilize all the volume of the opened vials, reducing thus the overall cost; † antibody monitoring, is preferred to booster injections. Every six months for those at risk of exposure to high concentrations of live rabies virus (e.g., laboratory workers dealing with rabies virus and other lyssaviruses), and every two years for those not at continuous risk of exposure (e.g., veterinarians and animal health officers); § at exceptional circumstances and when it is not possible to complete post-exposure prophylaxis with the same CCEEV, a rabies CCV fulfilling the WHO requirements should be used.
We collected current national human vaccination recommendations across Asia to summarize and highlight differences and similarities, and to identify best practices. The ultimate aim was to increase knowledge of current needs and identify gaps, in turn encouraging adoption of uniform rabies vaccination methods across all countries to ensure optimization of resource utilization.
Methods
We aimed to retrieve national guidelines on management of human rabies exposures from 21 Asian countries: Bangladesh, Bhutan, Brunei, Cambodia, China, Hong Kong, India, Indonesia, Japan, Lao People's Democratic Republic (PDR), Malaysia, Myanmar, Nepal, Pakistan, Philippines, Republic of Korea, Singapore, Sri Lanka, Taiwan, Thailand, and Vietnam. The research for the guidelines was performed between January and March 2017. Our investigation included scientific literature review searches, Ministry of Health web pages, other web pages (e.g., travel information pages), surveillance platforms and databases, medical association guidelines, publications for healthcare professionals and the public, and personal communications with people working on the specific field in each country. English and country-specific websites were reviewed in the local language. Due to the nature of this research, systematic review methods could not be applied. Indeed, national guidelines are not expected to be necessarily published in scientific journals, hence this work did rely mostly on information provided by Ministry of Health websites (often in local language), by national experts, etc. Findings were classified by document type, publisher, and year of publication. We aimed (a) to summarize PEP and PrEP recommendations and compare them to the WHO recommendations; (b) to explore variations between countries in human rabies prophylaxis and discuss opportunities for a harmonized approach; (c) to identify pitfalls and drawbacks in the adaptation of successful human rabies treatment and prophylaxis programs sufficiently harmonized with the WHO recommendations; (d) to highlight best practices.
Findings

Overall Findings
We retrieved national vaccination guidelines from 13 of the 21 countries considered: Bangladesh [23] , Bhutan [24] , Cambodia [25] , China [26] , India [27, 28] , Indonesia [29] , Malaysia [30] , Pakistan [31] , Philippines [32] , Sri Lanka [33] , Taiwan [34] , Thailand [35] , and Vietnam [36] . Official documents, outlining current rabies prevention and treatment practices, were retrieved for Hong Kong [37] [38] [39] , Japan [40] , Lao PDR [41] , and the Republic of Korea [42] . The national guidelines retrieved were usually issued by the Ministry of Health. We did not succeed to retrieve national documentation for four countries: Brunei, Myanmar, Nepal, and Singapore ( Figure 1 and Table 2) .
As expected, all national guidelines were considerably detailed and incorporated the WHO recommendations for PrEP and PEP vaccination. All recommended vaccines were cell culture vaccines and embryonated egg-based vaccines (CCEEVs). The schedules are summarized in Table 2 . Overall characteristics are given below.
Post-Exposure Prophylaxis (PEP)
Wound Care
Overall, the WHO recommendations for wound management are consistent in national guidelines. The guidelines from China [26] , India [27] , and Pakistan [31] were more detailed than others, containing explicit recommendations for wound care with photographs. The Indian [27] , Pakistani [31] , Philippine [32] , and Sri Lankan [33] guidelines recommend avoidance of wound suturing to allow for antibody (RIG) diffusion throughout the tissues, unless there is life-threatening bleeding. The Pakistani guidelines recommend daily dressing instead of suturing, except for very loose suturing for severe facial bites, with proper suturing 2-3 days after initial wound management [31] . Cauterization is no longer recommended in India as it does not offer additional benefit over washing while tetanus and antibiotics should be given if required, and if sepsis prevention is needed [27] . The Philippines recommend adhesive strips as an alternative to suturing, and also include detailed recommendations on antibiotic treatment [32] . In Sri Lanka, wound dressing is recommended, but not suturing [33] . 
RIG
Most guidelines follow WHO recommendations regarding RIG administration; however, there are some concerns related to the associated cost. Thus, for Lao PDR, the 2000 WHO report shows that RIG is rarely used due to its high cost [41] , and in a number of countries [25, 32, 35] , equine immunoglobulin (ERIG) is more commonly used than human immunoglobulin (HRIG) because it is cheaper and therefore more commonly available for free. The Philippine guidelines also contain details on the size of needles, skin tests to check whether human RIG should be preferred, special considerations for bites to the finger and toes, and they recommend HRIG for multiple bites and in symptomatic patients infected with human immunodeficiency virus (HIV) [32] .
PEP Vaccination Schedules
•
The 5-dose Essen, 4-dose Zagreb, or both schedules were the regimens of choice for IM administration. The Essen is used in Bhutan, Cambodia, China, India, Philippines, Sri Lanka, Taiwan, Thailand, Vietnam; and Zagreb in Bangladesh, Cambodia, China, Indonesia, Pakistan, Philippines, Sri Lanka ( Table 2 ). The 4-dose shortened Essen was the regimen of choice in the Malaysian recommendations, and was also recommended in the guidelines of Philippines (Tables 2 and 3 ).
We found recommendation for ID administration in 9 of the 13 retrieved national guidelines; the guidelines of China, Indonesia, Malaysia, and Taiwan do not include such recommendation (Tables 2  and 3 ). Also in the official documents retrieved for Japan and Lao PDR we did not find ID recommendations (Tables 2 and 3 ). All guidelines with ID recommendation suggested the updated Thai Red Cross regimen (Tables 2 and 3 ).
The Japanese guidelines recommend only subcutaneous (SC) administration as shown in Table 2 . 
RIG
PEP Vaccination Schedules
•
We found recommendation for ID administration in 9 of the 13 retrieved national guidelines; the guidelines of China, Indonesia, Malaysia, and Taiwan do not include such recommendation (Tables 2 and 3 ). Also in the official documents retrieved for Japan and Lao PDR we did not find ID recommendations (Tables 2 and 3 ). All guidelines with ID recommendation suggested the updated Thai Red Cross regimen (Tables 2 and 3 ).
Sri Lanka
Protocol for anti-rabies post exposure therapy [33] Director General of Health Services 1-1-1-1) (2-0-1-0-1 or 2-1-1) 
4-Dose Zagreb
4-Dose Essen
(1-1-1-1-0) Updated Thai Red Cross (2-2-2-0-2)
PEP Vaccination for Re-Exposed Individuals
Not all guidelines advise on the post-exposure management that should be followed when an individual who has previously received rabies vaccination is re-exposed ( Table 2 ). The guidelines of Bangladesh [23] , Bhutan [24] , China [26] , India [27] , and Philippines [32] recommend new full vaccination when previous full exposure cannot be documented or is uncertain.
Pre-Exposure Prophylaxis (PrEP)
PrEP Vaccination Schedules
With the exception of Japanese guidelines, all other guidelines recommend IM or ID vaccination schedules (Table 2) . IM administration is included in all of the 13 retrieved national guidelines. ID is included in only seven national guidelines, these of Bangladesh, Bhutan, Cambodia, Pakistan, Philippines, Sri Lanka, and Thailand ( Table 2 ). The Malaysian interim guidelines do not include any reference to PrEP [30] .
Booster after PrEP Vaccination
Eight national guidelines include booster recommendations and there are differences between countries; all relevant recommendations are described in detail in Table 2 . For individuals working under a high risk (laboratory workers dealing with rabies virus and other lyssaviruses) or continuous risk (veterinarians and animal health officers) of exposure to rabies, all recommendations agree that a booster vaccination should be given when antibody titers fall below 0.5 IU/mL.
Vaccination Recommendations for Special Populations
We found PEP recommendations for special populations in the guidelines of Bangladesh [23] , Bhutan [24] , Cambodia [25] , China [26] , India [27] , Malaysia [30] , Pakistan [31] , Philippines [32] , and Sri Lanka [33] . Chinese guidelines have an additional entry for PrEP recommendations in those populations [26] .
PEP recommendations
•
Pregnant and lactating women: The guidelines of Bangladesh, Bhutan, Cambodia, India, Pakistan, Philippines, and Sri Lanka state that there is no contraindication for vaccination in this population. The Chinese guidelines do not directly state whether PEP should be given or not, however they make reference to studies demonstrating that rabies vaccines are safe for pregnant women and for the fetus.
• Aged population and individuals with comorbidities: the same as above in the guidelines of Bangladesh, India, Pakistan, Philippines, and Sri Lanka.
Immunocompromised population: full PEP and IM route is recommended in the guidelines of Bangladesh, Bhutan, India, Malaysia, Philippines, and Sri Lanka. There is no special reference to this population in the guidelines of Cambodia and Pakistan. Chinese guidelines indicate that passive immunization can be administered in patients with immunodeficiency disorder and that the antibody response should be closely monitored.
• Individuals on treatment for malaria taking chloroquine: ID is contraindicated and IM is recommended in the guidelines of Bangladesh, Cambodia, India, Malaysia, Pakistan, Philippines, and Sri Lanka.
Other populations: Philippine's guidelines also note that IM is contraindicated for individuals with hematologic conditions, for whom the ID route should be chosen and that ID is contraindicated for individuals with chronic liver disease.
Chinese PrEP recommendations: Only in the Chinese guidelines, we found recommendations specific to PrEP. According to these, PrEP can be delayed in case of (a) pregnancy; (b) acute febrile disease or other acute disease; (c) active chronic disease; (d) use of steroids and immunosuppressive products. PrEP is not recommended for patients with immunodeficiency disease.
Discussion
Characteristics of Human Rabies Burden
In endemic areas rabies disease is largely underreported, and reliable occurrence data are often scarce or non-existent [2, 3, 43] . Patients often seek no treatment [44] , and some leave hospital against medical advice believing there is no cure [45] or because treatment cannot be offered [3] . Laboratory confirmation is sought in only a limited number of cases [44, 46] because of limited resources and training [46, 47] . Information systems for the collection of rabies cases may not be available [46] and often local authorities do not report rabies cases to central authorities [44, 46] . In many countries, the officially reported numbers of rabies cases and deaths are substantially lower than the actual numbers [1] . In Cambodia for example, the incidence of human rabies deaths was estimated to be 5.8 per 100,000, which was 15 times higher than the officially reported incidence [48] .
Younger children who are unable to protect themselves are at higher risk because they may interact with dogs in a manner perceived as threatening by the animal, e.g., stepping on the tail or trying to play when the dogs are eating [3, 4, 49, 50] . Because of their smaller stature, children are more prone to get bitten multiple times on the face, head, and neck, being thus exposed to the more severe type of bites with the shortest incubation period [51, 52] . Furthermore, children do no not always report minor bites or exposures by licks to their parents [52, 53] .
Rabies: An Unjustified Disease Burden
The development of vaccines against rabies started 100 years ago, and highly effective life-saving vaccines are currently available [19] . There is also a heightened awareness of rabies symptoms and inevitable fatal outcome without appropriate treatment [5, 54, 55] . Despite these advances, important knowledge gaps still exist. For example there are still those unaware that the wound must be immediately washed with soap and water [55, 56] , or that a laboratory test can confirm or reject suspected rabies in biting animal [55] . Furthermore, the rural population has limited access to vaccination centers as they are usually located in big cities, many animal bite victims do not seek medical care, and most infected individuals die at home [2, 13] . In addition, RIG is often not made available because a large fraction of the population cannot afford it [56, 57] . Poor people, living far from vaccination centers cannot afford to travel back-and-forth for injections, even if the vaccine is provided free of charge, and they often fail to complete complicated vaccination schedules [48, 56] . The problem is further accentuated by a lack of access to vaccines and RIG globally.
Rabies Vaccination Schedules Across Asia: Current Situation
PEP Recommendations
Adequate wound cleaning can reduce the number of infectious viral particles inoculated via saliva during the bite from the rabid animal [58] . Improper or incomplete wound care is one of the reasons for PEP failure [59] . Thorough washing of the wound can eliminate or substantially reduce the viral load [60] . Unfortunately, this critical intervention is often undervalued or ignored [60] . The level of detail on wound washing techniques were highly heterogeneous in the national guidelines, suggesting a local need for specific operational guidelines on wound treatment.
Although international guidelines on the provision of RIG are clear, local recommendations are often different and almost universally the use of RIG in practice is not aligned to international recommendations due to significant access barriers [61] .
The 5-dose Essen and 4-dose Zagreb IM regimens are considered equivalent in countries where both are recommended, except for the Bangladeshi guidelines that clearly favor the Zagreb regimen. The Zagreb regimen, however, is not endorsed by all national guidelines.
ID PEP vaccination was endorsed in nine national guidelines; however, the value of ID administration in reducing costs was not considered regarding PEP in six national guidelines or other official documents. Clearly, there is still a need to emphasize the cost savings achieved using ID administration as opposed to the cost of the five IM regimen of similar vaccine efficacy. However, these cost savings can only occur in facilities with well-trained staff and with sufficient patients presenting with bite wounds to ensure that the maximum number of doses are extracted per vial of vaccine. With no preservative in the available vaccines, the vial should not be left open for longer than 6-8 h [1, 13] and for smaller clinics this will not result in any cost saving vs. IM.
There are limited recommendations on the vaccination of patients who have a history of vaccination against rabies (PEP or PrEP). This could lead to overtreatment of patients presenting for treatment on multiple occasions. Given the risk factors for being bitten are associated with socio-economic factors, e.g., rural environments, working outdoors, it is likely that those who receive a bite are at a higher risk of subsequent bites than the general population. As such, multiple exposures are likely to occur. Clearer guidance could result in reduced use of vaccine and, where available, RIG for these patients.
Pregnancy, lactation, infancy, older age and comorbidities are not considered contraindications in the few guidelines that make reference to vaccination for special populations. Immunosuppressed individuals might have an inadequate antibody response in rabies PEP; however, specific recommendations can be found in very few guidelines.
PrEP Recommendations
Most country recommendations on patients for whom PrEP should be considered are aligned to WHO. Although recommendations are in place, uptake remains low because of complicated schedules, cost, and competing priorities especially within the context of limited PEP vaccine supply or resources for rabies control [62] . Less complicated vaccination schedules with shorter regimens and fewer doses would make PrEP simpler and reduce associated costs [62] . In addition, educational campaigns and rabies prevention and elimination programs should be conducted in areas where the infection rate is high; one such program was introduced in 2007 in the Bohol district of the Philippines, an area with the highest rabies incidence in the country [63] . The program included free routine PrEP for children aged 5-14 years and lasted four years (2007-2010) [52, 62] . Up to April 2010, this program achieved high PrEP vaccination coverage (47%) of the target population [62] .
Booster recommendations are not included in all guidelines and this may become an additional impediment to the optimal use of PrEP as there is little agreement on duration of protection or clinical benefit. Guidelines are more established for individuals at continual risk (lab workers, veterinarians, animal health workers) than for individuals at increased risk (children living in endemic areas, or travelers), and the intervals for serological follow-up (a test that is not consistently available everywhere) vary. It should also be noted that serological follow-up, even when recommended, is rarely practical or affordable. PrEP may be associated with cost savings because a previously vaccinated person needs shorter PEP and no RIG [62] . Children may benefit from receiving PrEP from 1 year of age and clear boosting recommendations are needed [62] .
Country-Specific Information for Countries Whose National Guidelines Were Not Retrieved
In Hong Kong public hospitals, 10,255 individuals received PEP between 2000 and 2004, all of whom received rabies vaccine and 1% also received RIG [38] . The country's rabies control program contains disease surveillance systems, laboratory diagnostic testing, PEP, and wound management [38] .
For Lao PDR, the SEARS initiative (South-East Asia Rabies Strategy, 2013) indicates the rabies control program was not clearly defined, human resources were short, the surveillance system was inadequate, and laboratory confirmation was unavailable [64] .
Brunei and Singapore are considered as free-of-rabies areas [43] . Singapore has been free from rabies since the 1950s and this was achieved through specific legislation, with which several rabies prevention strategies were implemented [43] .
For Myanmar, the Association of Southeast Asian Nations 2016 report drew attention to the lack of a national rabies control strategy, low level of awareness and surveillance, and limited funding for rabies control [43] .
In Nepal, public hospitals provide free post-exposure vaccination since 2007 [65] . RIG is available only in Kathmandu, and even there is mainly used by tourists and expats who can afford it [65] .
Future Perspective
The Sustainable Development Goals (SDG), established by the September 2015 UN General Assembly, included the target to end epidemics of Neglected Tropical Diseases (NTDs) by 2030 [66] . Coinciding with these SDGs, WHO and OIE in collaboration with the FAO and supported by the GARC, have jointly set the goal for rabies elimination by 2030 [3, 5] . Lessons learned from areas of the world where rabies has been successfully eliminated show that the "One Health" agenda will be the only way to achieve the 2030 goal of elimination of disease in Asia [5] . This framework resulted in substantial decrease in dog rabies incidence in 21 countries of Latin America and the Caribbean region, and several countries have been declared free of human rabies cases [67] . This was achieved thanks to a strong political commitment to control rabies in coordination with the Pan American Health Organization (PAHO). The program promoted mass canine vaccination, epidemiological surveillance, and provision of PEP and PrEP to people at risk. PEP became broadly available and, as part of the program, rabies vaccination centers were decentralized. PAHO's Veterinary Public Health Program provided technical support for a disease notification system and coordinated actions between Ministries of Agriculture and Health and the executive councils of the WHO and OIE. Community education and involvement was part of the program to engage people in mass dog vaccination. The educational resources of the GARC were used to achieve this. Mass media campaigns on the radio, and in schools, health facilities, and similar organizations were staged to convince people to have their dogs vaccinated [67] . Similarly, in 2015, the Pan-African Rabies Control Network was launched, to integrate the One Health approach in the 33 member states, aiming to meet the 2030 target [68] . In a similar way, the Association of Southeast Asian Nations (ASEAN) developed the ASEAN Rabies Elimination Strategy in a One Health approach, integrating political, organizational, sociocultural, and technical collaboration to achieve rabies elimination by 2020 in the ASEAN member states, plus China, Japan, and Korea [43] .
It is hoped that findings presented here might be useful to the authorities, health care providers, and patient organizations in the development and implementation of their initiatives for rabies elimination. This is more likely attainable through increased awareness of disease and encouraging the adoption of uniform rabies vaccination across Asia to ensure optimization of resource utilization, most often in resource-constrained environments. In that respect, the findings of the SAGE Working Group on rabies vaccines and rabies immunoglobulins will be highly significant.
To the best of our knowledge, this was the first work summarizing national rabies guidelines of the endemic Asian countries. However, we were unable to recover all national guidelines. Lack of information on vaccines' origin and shortages are further limitations. Our work could not retrieve real-life data on proportions of use of ID and IM; a future prospective study would be necessary in that respect.
Conclusions
National recommendations across these countries differ and while some guidelines are closely aligned to the WHO recommendations, other countries specify PEP schedules that are very demanding on resources. A lot of progress has been made with respect to rabies control programs in many countries; however, efforts should be continued through closer collaboration between human and animal health sectors to meet the 2030 goal for rabies elimination. These efforts will have the opportunity to incorporate the most current findings of the SAGE Working Group on rabies vaccines and rabies immunoglobulins.
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